ImmunityBio Inc
ImmunityBio Inc (IBRX) Implied Volatility Current
IBRX implied volatility is 95%. IV Rank is 23%, placing current premiums in the bottom of their 52-week range.
Read more
Tracking IBRX implied volatility helps you identify when options premiums on ImmunityBio Inc are historically cheap or expensive, and where the best trades are hiding. ImmunityBio Inc implied volatility reflects the market's expectation of future price movement: when IBRX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor ImmunityBio Inc's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For IBRX, tracking metrics like IBRX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on IBRX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co.
Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where IBRX implied volatility sits today versus where it has been. Our scanner ranks ImmunityBio Inc implied volatility against its historical range, surfaces extremes in IBRX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether ImmunityBio Inc IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is compressed vs the past year - options are relatively cheap, favoring buyers.
As of September 14, 2026
Trade options with IV on your side
Track IBRX IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→